Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael


Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles


Takeda Pharmaceutical Announces a Plasma-Derived Coronavirus Therapy

Plasma-derived therapies have proven effective in the treatment of severe acute viral respiratory infections.


Vir Biotechnology and Alnylam Join the Fight Against COVID-19

The two biotechs are expanding their existing collaboration with the goal of developing an antiviral treatment for the novel coronavirus.


3 Small-Caps That Are Soaring Because of Coronavirus Panic

Some of the top stocks in 2020 are the companies that are fighting the coronavirus.


Vir Biotechnology and WuXi Biologics to Collaborate on COVID-19 Treatment

News that the two biotechs are working together on monoclonal antibody treatments for the coronavirus has excited investors.


Ionis Pharmaceuticals' Revenues Rose 85% in 2019

The biotechnology company's license fees increased almost 400% to $490 million.


U.S. Health Official Warns: COVID-19 Will Hit the United States

Americans should prepare for the possibility that their lives will be disrupted due to the pandemic, says the CDC's Nancy Messonnier.


Intercept Pharmaceuticals Reports 40% Revenue Growth for 2019

The company's lead drug, Ocaliva, brought in $249.6 million last year.


These 2 Stocks Could Be 2020's Best Profit Opportunities

How do we find the top stock of 2020? The best performers in 2019 offer some clues.


A Plan to Use Blockchain to Stop Counterfeit Drugs Moves Forward

A host of major healthcare companies and drug retailers are collaborating on a system to combat fake drugs.


Anika Therapeutics Beats Revenue and Earnings Estimates

A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.


3 High-Growth Stocks Whose Gains Are Just Getting Started

These young companies have already delivered big returns for their shareholders, and there's every reason to expect more to come.


Vir Bio Identifies 2 Antibodies That Might Stop Coronavirus

Antibody-based treatments can be used both to protect people from infection and to treat those already affected.


Ionis Receives Orphan Drug Designation From EMA

The company is advancing a new treatment for people with Alexander disease.


Myriad Genetics CEO Mark Capone Resigns

The molecular diagnostics company also delivered an earnings miss, and its stock plunged.


Alnylam Beats Revenue Estimates, but Misses on Earnings

Shares of the genetic disease specialist were essentially flat in late afternoon trading.


Abiomed Crushed Its Earnings Estimates, but the Market Wasn't Impressed

The medical device maker's stock dropped 9%, then recovered.


3 Top Small-Cap Stocks to Buy in February

An insurance-shopping portal, a U.K. software company, and a Brazilian medical school operator all have potential for outsize returns.


Why Did Karuna Therapeutics Pop 26% in January?

The volatile biotech has been up and down since its massive gain back in November.


2 Top Healthcare Stocks to Buy Right Now

These two biotechs have major drugs that should be hitting the market soon.


Why Sea Stock Was Up 12.5% in January

The Singapore internet giant might be entering the banking business.